Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer

摘要

Abstract Objective Synchronous endometrial and ovarian cancer with endometrioid histology at two cancer sites typically presents with early-stage disease and is thought to have a good prognosis. We examined the survival of women with early-stage endometrioid endometrial cancer who had synchronous early-stage endometrioid ovarian cancer. Methods This is a retrospective case-control study examining the Surveillance, Epidemiology, and End Result Program between 1973 and 2013. Survival of women with stage I endometrioid endometrial cancer with stage I endometrioid ovarian cancer (n=839) were compared to women with stage I endometrioid endometrial cancer without synchronous ovarian cancer (n=123,692) after propensity score matching. Results Women with synchronous stage I endometrioid ovarian cancer were more likely to be diagnosed recently, be younger, have stage IA disease, grade 1 tumors, to have undergone lymphadenectomy, and were less likely to receive radiotherapy compared to those without synchronous ovarian cancer (all, P versus 95.3%, P =0.97) or overall survival (85.6% versus 87.2%, P =0.10). Among tumors with concordant grades at the two cancer sites, survival was similar regardless of presence of synchronous ovarian tumors (grade 1 tumors, 10-year rate for overall survival, 88.2% versus 89.1%, P =0.40; and grade 2 tumors, 84.0% versus 85.8%, P =0.78). Conclusion Women with stage I endometrioid endometrial cancer with synchronous stage I endometrioid ovarian cancer have a survival outcome similar to those with stage I endometrioid endometrial cancer without synchronous ovarian cancer. Highlights " Synchronous endometrial and ovarian cancer (SEOC) is not a rare clinical entity. " Historically women with SEOC have known to have a good prognosis. " This study compared survival of stage I endometrioid SEOC to non-SEOC. " Stage I endometrioid SEOC and stage I non-SEOC had similar survival outcomes. " Concordant tumor grade was not associated with survival for stage I SEOC.